The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma:

Related Experiment Video

Updated: Aug 2, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.8K

Yanxi Deng1, Fang Wang1, Xinhui Wu2

  • 1Clinical Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Frontiers in Pharmacology
|April 17, 2023
PubMed

Insights

This study identifies MX2 as a key gene involved in sunitinib resistance in clear cell renal cell carcinoma (ccRCC). Knocking down MX2 inhibits cancer cell proliferation, suggesting its potential as a therapeutic target for ccRCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sunitinib is a primary treatment for clear cell renal cell carcinoma (ccRCC).
  • Acquired drug resistance frequently limits the efficacy of sunitinib therapy in ccRCC patients.
  • Understanding the molecular mechanisms of sunitinib resistance is crucial for improving treatment outcomes.

Purpose of the Study:

  • To explore potential biological mechanisms underlying sunitinib resistance in ccRCC.
  • To identify novel genes associated with sunitinib resistance.
  • To investigate the role of identified genes, particularly MX2, in ccRCC progression and the tumor microenvironment.

Main Methods:

  • Analysis of publicly available gene expression data (GSE64052, GSE76068, TCGA) using R software.
  • Quantitative Real-Time PCR to detect gene RNA levels.
  • Construction of sunitinib-resistant ccRCC cell lines.
  • In vitro assays including Colony Formation and Cell Counting Kit-8 to assess cell proliferation.

Main Results:

  • Identified IFITM1, IL6, MX2, PCOLCE2, RSAD2, and SLC2A3 as genes associated with sunitinib resistance.
  • MX2 was further investigated for its role in ccRCC and its potential as an immune-related gene affecting immunotherapy response.
  • In vitro experiments confirmed MX2 overexpression in resistant cells and demonstrated that MX2 knockdown inhibits proliferation in sunitinib-resistant ccRCC cells.

Conclusions:

  • This study elucidates potential biological mechanisms driving sunitinib resistance in ccRCC.
  • MX2 is identified as a significant gene involved in sunitinib resistance and ccRCC progression.
  • MX2's role in the ccRCC microenvironment and potential impact on immunotherapy response warrant further investigation.
Keywords:
MX2biologicalccRCCepigeneticsunitinib

More Related Videos

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

721
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K